Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-Baclofen
- Development stage
- Phase 1
- Lead developer
- Amneal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intrathecal
01
Overview
L-Baclofen is a small molecule and the L-enantiomer of baclofen, functioning as a Gamma-aminobutyric acid B (GABA(B)) receptor agonist. It increases GABAergic neurotransmission in the central nervous system. It has been investigated for various neurological conditions, including refractory trigeminal neuralgia, tinnitus, movement disorders in dystonia-choreoathetosis cerebral palsy, and neuropathic pain. Studies have also explored its effects on spasticity and its influence on auditory pathways.
- Other names
- l-baclofenL: -baclofen
02
Targets
GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on L-Baclofen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on L-Baclofen.